Woodline Partners LP Sells 249,428 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Woodline Partners LP trimmed its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 50.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 245,676 shares of the company's stock after selling 249,428 shares during the quarter. Woodline Partners LP owned 1.64% of Jasper Therapeutics worth $5,253,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Wells Fargo & Company MN raised its stake in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics in the fourth quarter valued at $223,000. Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics in the fourth quarter valued at $266,000. Rhumbline Advisers raised its stake in shares of Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after purchasing an additional 1,652 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Jasper Therapeutics by 239.8% in the third quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company's stock valued at $308,000 after purchasing an additional 11,567 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Trading Up 4.0%

Shares of NASDAQ JSPR traded up $0.20 during mid-day trading on Thursday, hitting $5.31. The company had a trading volume of 136,194 shares, compared to its average volume of 293,074. The company has a market capitalization of $79.81 million, a price-to-earnings ratio of -1.12 and a beta of 2.74. Jasper Therapeutics, Inc. has a 1 year low of $3.13 and a 1 year high of $26.84. The stock's 50-day moving average price is $4.53 and its 200-day moving average price is $10.03.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). As a group, equities research analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on JSPR. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Oppenheimer reduced their target price on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Finally, UBS Group reduced their target price on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $62.22.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.